These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1955301)

  • 21. Therapeutic drug monitoring of antiepileptic drugs.
    Shakya G; Malla S; Shakya KN; Shrestha R
    JNMA J Nepal Med Assoc; 2008; 47(171):94-7. PubMed ID: 19079370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rational use of antiepileptic drug levels.
    Theodore WH
    Pharmacol Ther; 1992; 54(3):297-305. PubMed ID: 1465479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum aspirin-esterase activity in epileptic patients receiving treatment with phenobarbital, phenytoin, carbamazepine and valproic acid.
    Puche E; Garcia de la Serrana H; Mota C; Saucedo R
    Int J Clin Pharmacol Res; 1989; 9(1):55-8. PubMed ID: 2496043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humoral and cellular immune parameters in untreated and phenytoin-or carbamazepine-treated epileptic patients.
    Başaran N; Hincal F; Kansu E; Ciğer A
    Int J Immunopharmacol; 1994 Dec; 16(12):1071-7. PubMed ID: 7705969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in serum immunoglobulin levels during phenytoin treatment of epilepsy.
    Aarli JA
    Acta Neurol Scand; 1976 Nov; 54(5):423-30. PubMed ID: 998166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valproic acid and phenytoin effects on serum proteins and immunoglobulins of epileptic patients.
    Garzón P; González-Cornejo S; Román-Maldonado S; Navarro-Ruiz A
    Gen Pharmacol; 1985; 16(4):411-3. PubMed ID: 2412936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacotherapy of epilepsy--current problems and controversies].
    Schmidt D
    Fortschr Neurol Psychiatr; 1983 Nov; 51(11):363-86. PubMed ID: 6418628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of therapeutic drug monitoring of antiepileptic drugs.
    Irshaid YM; Hamdi AA; Al Homrany M
    Int J Clin Pharmacol Ther; 2003 Mar; 41(3):126-31. PubMed ID: 12665161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of effect of clonazepam on serum levels of diphenylhydantoin, phenobarbital and carbamazepine.
    Johannessen SI; Strandjord RE; Munthe-Kaas AW
    Acta Neurol Scand; 1977 Jun; 55(6):506-12. PubMed ID: 878840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive functions, epileptic syndromes and antiepileptic drugs.
    Bittencourt PR; Mader MJ; Bigarella MM; Dóro MP; Gorz AM; Marcourakis TM; Ferreira ZS
    Arq Neuropsiquiatr; 1992 Mar; 50(1):24-30. PubMed ID: 1307474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of serum lipids and lipoprotein (a) levels in epileptic children treated with carbamazepine, valproic acid, and phenobarbital.
    Castro-Gago M; Novo-Rodríguez MI; Blanco-Barca MO; Urisarri-Ruíz de Cortázar A; Rodríguez-García J; Rodríguez-Segade S; Eirís-Puñal J
    J Child Neurol; 2006 Jan; 21(1):48-53. PubMed ID: 16551453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measuring anti-convulsant levels in the accident and emergency department.
    McGlone R; Pritty P
    Arch Emerg Med; 1986 Jun; 3(2):141-3. PubMed ID: 3730081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Respiratory disease in patients with epilepsy on single-drug therapy with carbamazepine or phenobarbital.
    Gilhus NE; Strandjord RE; Aarli JA
    Eur Neurol; 1982; 21(4):284-8. PubMed ID: 7117316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variability of phenytoin, carbamazepine and valproate concentrations in a clinic population.
    Leppik IE
    Epilepsy Res Suppl; 1988; 1():85-90. PubMed ID: 3149581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum of concentrations of immunoglobulins in patients with epilepsy treated with carbamazepine.
    Strandjord RE; Johannessen SI; Aarli JA
    Acta Neurol Scand; 1980 Apr; 61(4):260-3. PubMed ID: 6769290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epilepsy and IgA deficiency--the effect of sodium valproate.
    Joubert PH; Aucamp AK; Potgieter GM; Verster F
    S Afr Med J; 1977 Oct; 52(16):642-4. PubMed ID: 337537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of the effectiveness of monotherapy in the treatment of epilepsy].
    Brignolio F; Verzè L; Baruchello M
    Minerva Med; 1991 Dec; 82(12):859-62. PubMed ID: 1780094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Further observations on carbamazepine plasma levels in epileptic patients. Relationships with therapeutic and side effects.
    Monaco F; Riccio A; Benna P; Covacich A; Durelli L; Fantini M; Furlan PM; Gilli M; Mutani R; Troni W; Gerna M; Morselli PL
    Neurology; 1976 Oct; 26(10):936-73. PubMed ID: 986584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct serum injection high-performance liquid chromatographic method for the simultaneous determination of phenobarbital, carbamazepine and phenytoin.
    Rainbow SJ; Dawson CM; Tickner TR
    J Chromatogr; 1990 May; 527(2):389-96. PubMed ID: 2201693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum immunoglobulins, complement levels and lymphocyte subpopulations in phenytoin-treated epileptic patients.
    Başaran N; Kansu E; Hincal F
    Immunopharmacol Immunotoxicol; 1989; 11(2-3):335-46. PubMed ID: 2621321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.